Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma

Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma

“…Smoking, alcohol use, dietary risk factors, mobile phone electrical radiation, severe head trauma, occupational risk factors, and exposure to pesticides have not been associated with GBM. 22,23 Because they cause cancer in animal tests, some pesticides and other agricultural compounds, such as organochlorides and alkylureas coupled with copper sulphates, have been suspected. Case-control and cohort studies of agricultural labourers, however, have shown outcomes that are equally negative or positive in terms of the risk of brain tumors.…”

“…50-80% of human This journal is © The Royal Society of Chemistry 2024 low-grade brain tumors, 50% of anaplastic gliomas, and about 5% of glioblastomas have IDH1 alterations. 49 Additional studies have demonstrated that the IDH1 mutation is a standalone indication predictor of a good prognosis. IDH1 with a mutation performs its abnormal function by converting alpha ketoglutarate to 2-hydroxyglutarate although its function might go beyond epigenetic changes.…”

“…Nanomedicine represents a paradigm shift, offering targeted, precise, and versatile strategies that address the shortcomings of conventional glioblastoma treatments. 49 Natural products containing antioxidant phytochemicals can be loaded into nanocarriers that have positive impacts on oxidative stress and cancer. Likewise, artificial intelligence plays a vital role in the therapy of glioblastoma by the controlled release of the drug from the cargo and evaluation of the pharmacokinetic parameters.…”

TransResUNet: Revolutionizing Glioma Brain Tumor Segmentation Through Transformer-Enhanced Residual UNet

“…They exhibit swift expansion, invasive tendencies, and resilience against conventional therapies [11]. Unfortunately, glioblastomas are associated with a poor prognosis, with most patients surviving only around 12 to 18 months following diagnosis [12], even with aggressive treatment approaches such as surgery, radiation therapy, and chemotherapy. The challenges in treating highgrade gliomas stem from their ability to invade surrounding brain tissue and their resistance to complete surgical removal or targeted therapies.…”